Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C. and Inzucchi, S.E., EMPA-REG Outcome Investigators (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128.

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.